Consultant, Department of Urology, Singapore General Hospital (SGH)

• Speaker, Oncology, and Cancer and Stem Cell Biology Plenary, 17 Sep 2021

Dr Tay Kae Jack is the Director of Urologic Oncology and a Consultant Urologist at the SGH. He completed his urology residency at the Singapore General Hospital and his fellowship at Duke University, North Carolina, USA. Dr Tay’s clinical practice includes focal therapy for prostate cancer, robotic pelvic surgery, complex resections of genitourinary (GU) cancers in the pelvis and retroperitoneum, and metastatic prostate cancer. He is an Adjunct Assistant Professor at the Duke-NUS Medical School Singapore and is the Principal Investigator for a Phase II trial of Focal Cryotherapy for Prostate Cancer. He currently holds a National Medical Research Council grant for prostate cancer risk stratification, advanced imaging, biopsy, active surveillance, cryotherapy and focal therapy.

Dr Tay has written more than 70 publications on the topic of urologic cancer. He collaborates on several international multicentre projects including the Cryo On-Line Data (COLD) registry and the Shared Equal Access Regional Cancer Hospital (SEARCH) database. He has participated in several international expert consensuses on prostate focal therapy including the International Consultation of Urological Diseases (ICUD) consensus on follow-up surveillance after prostate focal therapy and an international consensus on Patient Selection for Prostate Focal Therapy.

Dr Tay is also a Board Member for the Focal Therapy Society and is the current chairman of its Website and Social Media Committee. He aims to develop better risk stratification methods for localised and metastatic prostate cancer and a modern approach to precision medicine in prostate cancer.